ライフサイエンスコーパス: interleukin-13

1 nterleukin 4, interleukin 5, interleukin 10, interleukin 13).

2 acrophages, polarized with interleukin-4 and interleukin-13.

3 beta1, connective tissue growth factor, and interleukin-13.

4 of CD4+ T cells producing interleukin-4 and interleukin-13.

5 canonical T(H)2 cytokines interleukin-4 and interleukin-13.

6 lic esophagitis, including interleukin-5 and interleukin-13.

7 tly reduced Th2 cytokines, interleukin-4 and interleukin-13.

8 h-2-type cytokines such as interleukin-4 and interleukin-13.

9 nes, in the first instance interleukin-4 and interleukin-13.

10 0, 95% CI 0.30-0.81, interaction p=0.02) and interleukin-13 (0.52, 0.34-0.82, 0.0005) response to tet

11 o had a pretreatment profile consistent with interleukin-13 activity.

12 ansforming growth factor beta1 (TGFbeta1) or interleukin-13, although active TGFbeta1 was present loc

13 ome 11, in a region containing the genes for interleukin 13 and granulocyte/macrophage-colony-stimula

14 9 cell lines in response to stimulation with interleukin 13 and lipopolysaccharide.

15 d the levels of predicted targets, including interleukin-13 and 3 tumor necrosis factor receptors (TN

16 f a recombinant chimeric protein composed of interleukin-13 and a mutated form of Pseudomonas exotoxi

17 id cells (ILCs), resulting in suppression of interleukin-13 and hallmark features of the allergic res

18 egulator analysis, we observed inhibition of interleukin-13 and IFN-gamma and dysregulation of biolog

19 ined elevated levels of interferon-gamma and interleukin-13 and increased levels of CCR1 ligands CCL3

20 olony-stimulating factor), and interleukins (interleukin-13 and interleukin-16).

21 Interleukin-13 and interleukin-4 were unable to block in

22 onchoalveolar lavage eosinophil counts, lung interleukin-13 and interleukin-5 levels, and airway hype

23 ment is under immune control by the cytokine interleukin-13 and the chemokine CXCL10.

24 elopment of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro.

25 ids in HMC-1 cells resulted in activation of interleukin-13 and tumor necrosis factor-alpha promoters

26 of two Th-2 cytokines (i.e., interleukin-5, interleukin-13) and one Th-1 cytokine (i.e., interferon-

27 in the concentration of interferon gamma and interleukin 13, and in the amount of proliferation betwe

28 of HIV infection, including interleukin 10, interleukin 13, and interleukin 22.

29 ate regulator of three genes, interleukin-4, interleukin-13, and interleukin-5, spread over 120 kilob

30 yte-macrophage colony-stimulating factor and interleukin-13, and natural killer cell enhancing factor

31 phageal eosinophilia and that interleukin-4, interleukin-13, and STAT6 contributed to a lesser extent

32 pe 2 (T2) inflammation through the action of interleukin-13, and that the interferon response to resp

33 tionally distinct sensory neurons, including interleukin-13- and leukotriene-responsive Nmu-hi cells

34 In contrast, with the exception of interleukin-13, anti-inflammatory cytokine production wa

35 Interleukin-4 and Interleukin-13 are cytokines critical to the development

36 However, it blocked interleukin-13 as evidenced by the effect on interleukin

37 Leishmania donovani-infected interleukin-13-/- BALB/c mice showed impaired initial ga

38 We have found that the primary interleukin-13-binding protein IL-13Ralpha2 chain plays

39 ssion, and the addition of interleukin-4 and interleukin-13 blockade with dupilumab resulted in rapid

40 tured mast cells secreted greater amounts of interleukin-13 but much less MIP-1beta and interleukin-6

41 tumorigenicity (ST2)-dependent production of interleukin-13 by eosinophils in the hepatoprotection ag

42 cently, we have shown that interleukin-4 and interleukin-13 can independently induce human macrophage

43 cells and that these cytokines, particularly interleukin-13, can act directly on airway smooth muscle

44 also led to a decrease in interleukin-4 and interleukin-13 concentrations, which drive the Th2 respo

45 childhood TBM based on CSF concentrations of interleukin 13 (cutoff value, 37.26 pg/mL), vascular end

46 LPS exposure, and increasing PI3K activity (interleukin-13) decreased release of prostaglandin E2 af

47 Interleukin 13-deficient (IL-13-/-) mice express a defec

48 Thus, it may be possible to promote interleukin-13-dependent hepatobiliary expansion without

49 By itself, interleukin-13 does not appear to materially influence a

50 t internalization of Candida albicans during interleukin-13-enhanced, MR-mediated phagocytosis.

51 ytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and cysteinyl leuko

52 to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenoty

53 ntly been reported for the interleukin-4 and interleukin-13 genes (IL4 and IL13) with the interleukin

54 Interleukin-13 has been implicated as a key factor in as

55 lonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asth

56 or 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in AML and vascular endothelial gr

57 uman natural killer (NK) cells revealed that interleukin 13 (IL-13) and interferon gamma (IFN-gamma)

58 Interleukin 13 (IL-13) is a key factor in fibrotic disea

59 The cytokine interleukin 13 (IL-13) is a major effector molecule for

60 ILC2-derived interleukin 13 (IL-13) is critical for eliciting product

61 Associations between interleukin 13 (IL-13) levels and aGVHD were by far the

62 We found high interleukin 13 (IL-13) levels in the bone marrow of MF m

63 to the lung, bred these mice with CC10-rtTA-interleukin 13 (IL-13) mice in which IL-13 was overexpre

64 The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab

65 ad elevated serum levels of the Th2 cytokine interleukin 13 (IL-13) on day 6 after T-cell transfer co

66 tain their function and selectively maintain interleukin 13 (IL-13) production via increased acquisit

67 cells in situ exhibit on their surfaces the interleukin 13 (IL-13) receptor designated IL13Ralpha2.

68 The level of the anti-inflammatory cytokine interleukin 13 (IL-13) was lower in the serum and lungs

69 Type 2 helper T cells (TH2 cells) produce interleukin 13 (IL-13) when stimulated by papain or hous

70 human airway epithelia with the Th2 cytokine interleukin 13 (IL-13), examining how this affected DPP4

71 fact, liver fibrosis, which is dependent on interleukin 13 (IL-13), increased by a factor of more th

72 response, characterized by the production of interleukin 13 (IL-13), which drives expulsion.

73 (IL-4)(-/-) BALB/c mice have indicated that interleukin 13 (IL-13), whose receptor shares the IL-4Ra

74 ting an activated phenotype and induction of interleukin 13 (IL-13)- and GATA3-expressing Th2-type CD

75 ix metalloproteinase 2 (MMP2), as part of an interleukin 13 (IL-13)-dependent regulatory loop, dampen

76 previously unknown pathway that required the interleukin 13 (IL-13)-IL-33 axis and cells of the non-T

77 -2 (Th2) [increased interleukin 5 (IL-5) and interleukin 13 (IL-13)] and T regulatory type-1 (Tr1) (I

78 In addition, this allergic response required interleukin-13 (IL-13) (the response was absent in IL-13

79 chanism dependent on interleukin-4 (IL-4) or interleukin-13 (IL-13) activation of signal transducer a

80 Interleukin-13 (IL-13) activation of the STAT6 signaling

81 (CB) is a recombinant protein consisting of interleukin-13 (IL-13) and a truncated form of Pseudomon

82 reater airway necrosis, and higher levels of interleukin-13 (IL-13) and airway mucin expression than

83 Interleukin-13 (IL-13) and IL-4 are cytokines produced b

84 Interleukin-13 (IL-13) and IL-4 concentrations were meas

85 (STAT6) is a critical up-stream mediator of interleukin-13 (IL-13) and IL-4 signaling and is constit

86 Here we show that interleukin-13 (IL-13) and its receptors IL-13Ralpha1 an

87 re of allergic lung disease, is regulated by interleukin-13 (IL-13) as well as the eotaxin chemokines

88 Interleukin-13 (IL-13) belongs to the IL-4 gene family.

89 te, suppression depended on the secretion of interleukin-13 (IL-13) by iNKT cells because an antibody

90 roup 2 innate lymphoid cells (ILC2s) release interleukin-13 (IL-13) during protective immunity to hel

91 have clearly demonstrated that the cytokine interleukin-13 (IL-13) effectively targets glioblastoma

92 Interleukin-13 (IL-13) has been linked to the pathogenes

93 Interleukin-13 (IL-13) has emerged as a major cytokine m

94 CNTO607 is a neutralizing anti-interleukin-13 (IL-13) human monoclonal antibody obtaine

95 t ITLN1 gene expression is highly induced by interleukin-13 (IL-13) in a subset of metaplastic MUC5AC

96 Despite the importance of interleukin-13 (IL-13) in systemic sclerosis (SSc) and o

97 We created a novel mutated form of human interleukin-13 (IL-13) in which a positively charged arg

98 We reported previously that interleukin-13 (IL-13) induces tyrosine phosphorylation/

99 Interleukin-13 (IL-13) is a critical mediator of pulmona

100 Interleukin-13 (IL-13) is a cytokine secreted by Th2 lym

101 Interleukin-13 (IL-13) is a cytokine that has been shown

102 Interleukin-13 (IL-13) is a mediator of pulmonary mucus

103 Interleukin-13 (IL-13) is a pleiotropic cytokine that ca

104 We found that the type 2 cytokine interleukin-13 (IL-13) is induced in exercising muscle,

105 Interleukin-13 (IL-13) is the dominant effector cytokine

106 nt protein-1 (MCP-1) and a later increase in interleukin-13 (IL-13) levels in the peritoneal cavity.

107 ates induced variable disease severity, lung interleukin-13 (IL-13) levels, and gob-5 levels in BALB/

108 h1) and Th2 cytokine mRNAs, we observed that interleukin-13 (IL-13) mRNA was highly expressed in HTLV

109 Deficient interleukin-13 (IL-13) production by NT cells and reduce

110 We have previously shown that aberrant interleukin-13 (IL-13) production by peripheral blood ef

111 Interleukin-13 (IL-13) receptor alpha2 (IL-13Ralpha2), a

112 Ls also had high levels of expression of the interleukin-13 (IL-13) receptor and downstream effectors

113 sed the signaling chain of the high affinity interleukin-13 (IL-13) receptor IL-13Ralpha1.

114 Exposure of the epithelium to interleukin-13 (IL-13) reconstituted the goblet cell hyp

115 T6 in KSHV-associated PEL cells results from interleukin-13 (IL-13) secretion and reduced expression

116 hat STAT6 activation tightly correlates with interleukin-13 (IL-13) secretion, JAK1/2 tyrosine phosph

117 te lymphoid cells (ILC2s) and their cytokine interleukin-13 (IL-13) signaled directly to inhibitory i

118 from wild-type BALB/c mice are polarized by interleukin-13 (IL-13) towards a tumor-promoting M2 phen

119 Likewise, CD4+ expression of interleukin-13 (IL-13) was increased (poor responders: 4

120 gh levels of the profibrotic type 2 cytokine interleukin-13 (IL-13) were produced following activatio

121 Interleukin-13 (IL-13), a multifunctional cytokine, has

122 Interleukin-13 (IL-13), a predominantly Th2-derived cyto

123 Interleukin-13 (IL-13), a T-helper 2 cytokine, is a key

124 Interleukin-13 (IL-13), a Th2 cytokine, plays a pivotal

125 uired group 2 innate lymphoid cells (ILC2s), interleukin-13 (IL-13), and its receptor, IL-4Ra-IL-13Ra

126 ansforming growth factor-beta (TGF-beta) and interleukin-13 (IL-13), cytokines implicated in remodeli

127 ion and is associated with the production of interleukin-13 (IL-13), in resistance to this nematode.

128 Therefore, we tested the hypothesis that interleukin-13 (IL-13), which influences the differentia

129 thmatic airways, HAE cells were treated with interleukin-13 (IL-13), which reduced viral titers, vira

130 Interleukin-13 (IL-13)-expressing follicular helper T (T

131 is induced via a T helper-2 (Th2)-specific, interleukin-13 (IL-13)-mediated pathway in epithelial ce

132 adoxically resulted in dramatic expansion of interleukin-13 (IL-13)-producing ILC2s and resistance to

133 etermined high-resolution structure of human interleukin-13 (IL-13).

134 iated cultured bronchial epithelial cells to interleukin-13 (IL-13).

135 of receptors for immune regulatory cytokine, interleukin-13 (IL-13).

136 crete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that ac

137 n type 2 T cells, we demonstrate that type 2 interleukin-13+ (IL-13+) T cells (CD4+ or CD8+) in human

138 those encoding human interleukin 4 (IL4) and interleukin 13 (IL13 ), which induce IgE class switching

139 Interleukin 13 (IL13) belongs to a family of cytokines w

140 Interleukin 13 (IL13) is a T-helper type 2 (Th2) cytokin

141 ), interleukin 4 (Il4), interleukin 5 (Il5), interleukin 13 (Il13), and granulocyte-macrophage colony

142 se associated with increased serum levels of interleukin 13 (IL13), which might contribute to its pat

143 n in healthy tissue, motivating expansion of interleukin 13 (IL13)-based chimeric antigen receptor (C

144 cancers (gliomas) express a receptor (R) for interleukin 13 (IL13).

145 es express large number of receptors (R) for interleukin 13 (IL13).

146 tail, 2 (KIR3DL2); interleukin 4 (IL4); and interleukin 13 (IL13).

147 Expression of the cytokine interleukin-13 (IL13) is critical for Th2 immune respons

148 Binding of interleukin-13 (IL13) or interleukin-4 (IL4) to the IL4

149 nted that alpha-helices A, C, and D in human interleukin-13 (IL13) participate in interaction with it

150 dating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis.

151 o too have monoclonal antibodies targeted to interleukin 13 in patients with a type 2 allergic phenot

152 or necrosis factor alpha, interleukin 4, and interleukin 13 in the liver and spleen, which are associ

153 The level of interleukin-13 in bronchoalveolar lavage fluid from MCMV

154 have revealed direct and distinct roles for interleukin-13 in fibrosis, steatosis, cholestasis, and

155 ecreased allergen-induced AHR, production of interleukin-13 in lung tissue, and lung eosinophilia.

156 report a role for the type 2 cytokine interleukin-13 in orchestrating metabolic reprogramming

157 a, goblet cell metaplasia, and expression of interleukin-13 in response to low-dose aerosolized aller

158 e-1 response, and enhanced interleukin-5 and interleukin-13 in the type-2 response.

159 dy of lebrikizumab, a monoclonal antibody to interleukin-13, in 219 adults who had asthma that was in

160 ell immunity that involves interleukin-5 and interleukin-13-induced esophageal epithelial cell respon

161 Interleukin-4 or interleukin-13 induction of monocyte-macrophage fusion p

162 d not, whereas antibodies to interleukin 10, interleukin 13, interferon alpha, or interferon gamma mo

163 evated production of interleukin 10 (IL-10), interleukin 13, interferon gamma, CXCL9, and CCL2 compar

164 leukin-10, interleukin-12/interleukin-23p40, interleukin-13, interleukin-17, interleukin-18, interfer

165 ory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophage inflammatory

166 interleukin-4, interleukin-5, interleukin-7, interleukin-13, interleukin-17, macrophage inflammatory

167 Interleukin 13 is a central mediator of asthma.

168 cells from the actions of interleukin 4 and interleukin 13, is used as treatment for severe allergic

169 numab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic tre

170 red receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflam

171 red receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflam

172 red receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation.

173 ortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolip

174 e by stimulating type 2 immunity, leading to interleukin-13-mediated epithelial and AMP expression ch

175 was observed to block the interleukin-4- or interleukin-13-mediated induction of CDw60 on cultured k

176 leukin-5, anti-interleukin-4Ralpha, and anti-interleukin-13 monoclonal antibodies in patients with se

177 In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation

178 Tralokinumab is a human interleukin-13 neutralising monoclonal antibody.

179 d antibodies against IgE, interleukin 5, and interleukin 13, offer hope to improve the quality of lif

180 effect of the cytokines interferon-gamma and interleukin-13 or interleukin-4 on keratinocytes, alone

181 h those identified by microarray analysis of interleukin-13-overexpressing and integrin-beta6-deficie

182 the substantial local efficacy of BTZ-043 in interleukin-13-overexpressing mice, which mimic human TB

183 ogressive models of liver disease induced by interleukin-13 overexpression or after infection with Sc

184 ng early ART had higher day-14 CSF levels of interleukin-13 (P = .04), sCD14 (P = .04), sCD163 (P = .

185 ncreased secretion of eotaxin in response to interleukin-13 (P = 0.04).

186 lity of DPP-4 and periostin as biomarkers of interleukin-13 pathway activation.

187 Biological agents directed against the interleukin-13 pathway and new immunoregulatory agents t

188 lonal antibody that blocks interleukin-4 and interleukin-13 pathways and has shown efficacy in five d

189 oplatform, when subsequently conjugated with interleukin-13 peptide IL-13-Gd3N@C80(OH)x(NH2)y, exhibi

190 te that this agent can be conjugated with an interleukin-13 peptide that is designed to target an ove

191 -affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleuki

192 macrophages stimulated with interleukin 4 + interleukin 13 produce arginase I, which decreases the e

193 ive immune response and is driven instead by interleukin-13 produced by macrophages that have been st

194 tly induces tuft cell expansion by promoting interleukin-13 production by innate lymphoid cells.

195 SLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model.

196 ore robust interleukin-4, interleukin-5, and interleukin-13 production than their mature naive counte

197 D4(+) and CD8(+) T cells are associated with interleukin-13 production.

198 nts (scFvs) against T cell CD3e and GBM cell interleukin 13 receptor alpha 2 (IL13Ra2).

199 have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).

200 ubsets, but Th1 cells express high levels of interleukin 13 receptor alpha1 (IL-13R alpha 1), which h

201 Interleukin 13 receptor alpha2 (IL-13R(alpha)2) chain is

202 olymorphonucleocyte (PMN) infiltration in an interleukin 13 receptor alpha2 (IL-13Ralpha2)-dependent

203 date intrathecal delivery of EPHA2, HER2 and interleukin 13 receptor alpha2 chimeric antigen receptor

204 three cell-surface targets, EPHA2, HER2 and interleukin 13 receptor alpha2, expressed on medulloblas

205 s, CCN proteins, fibroblast growth factor 2, interleukin 13 receptor components, proteases, antiprote

206 The interleukin-13 receptor (IL-13R) complex is composed of

207 ant glioma cell lines express high levels of interleukin-13 receptor (IL-13R).

208 GAAs were EphA2, interleukin-13 receptor alpha 2 (IL-13Ralpha2), and surv

209 rowth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Ralpha2), or CART-

210 actor receptor (EGFR), EGFR variant III, and interleukin-13 receptor alpha 2 (IL13Ralpha2) on glioma

211 epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Ralpha2).

212 cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Ralpha2).

213 class II, beta(2)-microglobulin, clusterin, interleukin-13 receptor alpha chain, ovotransferrin, a s

214 Interleukin-13 receptor alpha-1 chain (IL-13Ralpha1) bin

215 Interleukin-13 receptor alpha-2 (IL13Ralpha2) is a cell

216 r") platform into newly developed human anti-interleukin-13 receptor alpha-2 (IL13Ralpha2)-single-cel

217 Restricted and high-level expression of interleukin-13 receptor alpha2 (IL-13Ralpha2) in a major

218 The interleukin-13 receptor alpha2 (IL-13Ralpha2) is a cance

219 The high affinity interleukin-13 receptor alpha2 (IL13Ralpha2) is selectiv

220 Whereas interleukin-13 receptor alpha2 chain (IL-13Ralpha2) is o

221 lines have been reported to overexpress the interleukin-13 receptor alpha2 subunit (IL13Ralpha2) rel

222 ssion signature comprising a surface marker, interleukin-13 receptor subunit alpha 2 (IL13RA2), which

223 Although interleukin-13 receptors (IL-13R) are overexpressed on s

224 rcinoma (RCC) cells express large numbers of interleukin-13 receptors (IL-13R), a newly described hem

225 interleukin-13 as evidenced by the effect on interleukin-13-related pharmacodynamic biomarkers, and c

226 pwise progression (paligenosis) initiated by interleukin-13-secreting innate lymphoid cells (ILC2s).

227 GATA3-positive cells and the level of interleukin 13 secretion in response to P. falciparum-in

228 nd STAT6 signaling are critical mediators of interleukin 13 signaling in CMs.

229 Using transgenic mice with interleukin-13 signaling genetically disrupted in hepato

230 onoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosino

231 ously controlled but distinctly regulated by interleukin-13 signaling.

232 oclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediate

233 h2) response, or the pathogenic Th2 cytokine interleukin 13 significantly ameliorated pulmonary arter

234 have shown that the type 2 effector cytokine interleukin-13 simultaneously, yet independently, direct

235 eline (2.5-fold higher; p = 0.004) and after interleukin-13 stimulation (13-fold higher; p = 0.0001).

236 We hypothesized that anti-interleukin-13 therapy would benefit patients with asthm

237 ts for EoE: anti-interleukin-5 therapy, anti-interleukin-13 therapy, anti-IgE therapy, montelukast, c

238 een in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role in the physiologic

239 inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha receptor complexes

240 terleukin-9, interleukin-10, interleukin-12, interleukin-13, tumor necrosis factor-alpha, interferon-

241 body) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numer

242 ts secrete high levels of interleukin 10 and interleukin 13 upon in vitro restimulation, which are al

243 duction of CDw60 involving interleukin-4, or interleukin-13 was antagonized by interferon-gamma.

244 kin 1beta, interleukin 2, interleukin 6, and interleukin 13 were significantly greater in NW specimen

245 raction and MMP secretion in the presence of interleukin-13 were also observed.

246 am regulators of the core network, including interleukin 13, which induced CM cell cycle entry and ST

247 complexes of the cytokines interleukin-4 and interleukin-13 with their receptors, showing how events

248 tion (chemokines CCL17, CCL18, and CCL26 and interleukin 13) with preferential activation of the JAK1